|
 |
|
|||||||
|
|||||||||
© 2002 by the American Diabetes Association, Inc.
Pathophysiology/Complications |
Are Lower Fasting Plasma Glucose Levels at Diagnosis of Type 2 Diabetes Associated With Improved Outcomes?
U.K. Prospective Diabetes Study 61
1 Diabetes Center, Prince of Wales Hospital, Randwick, Australia
2 Diabetes Trials Unit, Oxford Center for Diabetes, Endocrinology and Metabolism, University of Oxford, Oxford, U.K
OBJECTIVE—Type 2 diabetes may be present for several years before diagnosis, by which time many patients have already developed diabetic complications. Earlier detection and treatment may reduce this burden, but evidence to support this approach is lacking.
RESEARCH DESIGN AND METHODS—Glycemic control and clinical and surrogate outcomes were compared for 5,088 of 5,102 U.K. Diabetes Prospective Study participants according to whether they had low (<140 mg/dl [<7.8 mmol/l]), intermediate (140 to <180 mg/dl [7.8 to <10.0 mmol/l]), or high (
180 mg/dl [10 mmol/l]) fasting plasma glucose (FPG) levels at diagnosis. Individuals who presented with and without diabetic symptoms were also compared.
RESULTS—Fewer people with FPG in the lowest category had retinopathy, abnormal biothesiometer measurements, or reported erectile dysfunction. The rate of increase in FPG and HbA1c during the study was identical in all three groups, although absolute differences persisted. Individuals in the low FPG group had a significantly reduced risk for each predefined clinical outcome except stroke, whereas those in the intermediate group had significantly reduced risk for each outcome except stroke and myocardial infarction. The low and intermediate FPG groups had a significantly reduced risk for progression of retinopathy, reduction in vibration sensory threshold, or development of microalbuminuria.
CONCLUSIONS—People presenting with type 2 diabetes with lower initial glycemia who may be earlier in the course of their disease had fewer adverse clinical outcomes despite similar glycemic progression. Since most such people are asymptomatic at diagnosis, active case detection programs would be required to identify them.
Abbreviations: ETDRS, Early Treatment of Diabetic Retinopathy Study • FPG, fasting plasma glucose • HOMA, homeostasis model assessment • UKPDS, U.K. Prospective Diabetes Study
CiteULike 
Del.icio.us 
Digg 
Reddit 
Technorati What's this?
This article has been cited by other articles:
|
|
 |
|
  P. Evans, P. Langley, and D. P. Gray Diagnosing Type 2 diabetes before patients complain of diabetic symptoms--clinical opportunistic screening in a single general practice Fam. Pract., September 1, 2008; (2008) cmn052v1. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Colagiuri and A. E. Walker Using An Economic Model Of Diabetes To Evaluate Prevention And Care Strategies In Australia Health Aff., January 1, 2008; 27(1): 256 - 268. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Janssen, K. Gorter, R. Stolk, and G. Rutten Low yield of population-based screening for Type 2 diabetes in the Netherlands: the ADDITION Netherlands study Fam. Pract., December 1, 2007; 24(6): 555 - 561. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. Eborall, R. Davies, A.-L. Kinmonth, S. Griffin, and J. Lawton Patients' experiences of screening for type 2 diabetes: prospective qualitative study embedded in the ADDITION (Cambridge) randomised controlled trial BMJ, September 8, 2007; 335(7618): 490 - 490. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. Blonde Easing the Transition to Insulin Therapy in People With Type 2 Diabetes The Diabetes Educator, July 1, 2007; 33(Supplement_7): 232S - 240S. [Full Text] [PDF]
|
|
|
|
 |
|
 D. M. Nathan, J. B. Buse, M. B. Davidson, R. J. Heine, R. R. Holman, R. Sherwin, and B. Zinman Management of Hyperglycemia in Type 2 Diabetes: A Consensus Algorithm for the Initiation and Adjustment of Therapy: A consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes Diabetes Care, August 1, 2006; 29(8): 1963 - 1972. [Full Text] [PDF]
|
|
|
|
|
|
T. Drivsholm and N. d. F. Olivarius General practitioners may diagnose type 2 diabetes mellitus at an early disease stage in patients they know well Fam. Pract., April 1, 2006; 23(2): 192 - 197. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. M. Eddy, L. Schlessinger, and R. Kahn Clinical Outcomes and Cost-Effectiveness of Strategies for Managing People at High Risk for Diabetes Ann Intern Med, August 16, 2005; 143(4): 251 - 264. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. L. Bakris, V. Fonseca, R. E. Katholi, J. B. McGill, F. H. Messerli, R. A. Phillips, P. Raskin, J. T. Wright Jr, R. Oakes, M. A. Lukas, et al. Metabolic Effects of Carvedilol vs Metoprolol in Patients With Type 2 Diabetes Mellitus and Hypertension: A Randomized Controlled Trial JAMA, November 10, 2004; 292(18): 2227 - 2236. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Colagiuri, Z. Hussain, P. Zimmet, A. Cameron, and J. Shaw Screening for Type 2 Diabetes and Impaired Glucose Metabolism: The Australian experience Diabetes Care, February 1, 2004; 27(2): 367 - 371. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. W. Ealovega, B. P. Tabaei, M. Brandle, R. Burke, and W. H. Herman Opportunistic Screening for Diabetes in Routine Clinical Practice Diabetes Care, January 1, 2004; 27(1): 9 - 12. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. W. Sleeman, K. Garcia, R. Liu, J. D. Murray, L. Malinova, M. Moncrieffe, G. D. Yancopoulos, and S. J. Wiegand Ciliary neurotrophic factor improves diabetic parameters and hepatic steatosis and increases basal metabolic rate in db/db mice PNAS, November 25, 2003; 100(24): 14297 - 14302. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Dhatariya Type 2 diabetes is cardiovascular disease J R Soc Med, August 1, 2003; 96(8): 371 - 372. [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Diabetes | Diabetes Care | Clinical Diabetes | Diabetes Spectrum |